A randomized, multicenter, open-label, phase 2 study of TRK-950 in combination with ramucirumab and paclitaxel as second-line therapy in patients with Caprin-1 positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma

被引：0
|
作者：
Kelly, Ronan Joseph
Castillo, Dani Ran
Yamaguchi, Kensei
Kato, Ken
Kudo, Toshihiro
Wainberg, Zev A.
Rha, Sun Young
Lee, Jeeyun
Ryu, Min-Hee
Okano, Fumiyoshi
Shitara, Kohei
机构：
[1] Baylor Univ, Charles A Sammons Canc Ctr, Med Ctr, Dallas, TX USA
[2] Loma Linda Univ, Div Med Oncol & Hematol, Sch Med, Loma Linda, CA USA
[3] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Gastroenterol Chemotherapy, Tokyo, Japan
[4] Natl Canc Ctr, Tokyo, Japan
[5] Osaka Int Canc Inst, Osaka, Japan
[6] Univ Calif Los Angeles, Los Angeles, CA USA
[7] Yonsei Univ, Coll Med, Seoul, South Korea
[8] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea
[9] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea
[10] Toray Industries Ltd, Yokohama, Kanagawa, Japan
[11] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4181
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A randomized, multicenter, open-label, phase 2 study of TRK-950 in combination with ramucirumab and paclitaxel as second-line therapy in patients with CAPRIN-1 positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
    Kelly, Ronan Joseph
    Rha, Sun Young
    Lee, Jeeyun
    Okano, Fumiyoshi
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS420 - TPS420
  • [2] Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Randomized, open-label, phase 3 KEYNOTE-061 study
    Ohtsu, A.
    Tabernero, J.
    Bang, Y. -J.
    Fuchs, C.
    Sun, L.
    Wang, Z.
    Csiki, I.
    Koshiji, M.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2015, 26
  • [3] A multi-center, randomized, open-label, phase III study of sintilimab plus ramucirumab as 1st-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-106)
    Xu, R.
    Li, Z.
    Ma, Z.
    Liu, Y.
    Wang, Y.
    Zhou, H.
    Yang, L.
    Li, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S929 - S930
  • [4] Pembrolizumab versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study.
    Ohtsu, Atsushi
    Tabernero, Josep
    Bang, Yung-Jue
    Fuchs, Charles S.
    Sun, Linda
    Wang, Zhen
    Csiki, Ildiko
    Koshiji, Minori
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies
    Shah, Manish A.
    Udrea, Anghel Adrian
    Bondarenko, Igor
    Mansoor, Was
    Sanchez, Raquel Guardeno
    Sarosiek, Tomasz
    Bozzarelli, Silvia
    Schenker, Michael
    Gomez-Martin, Carlos
    Morgan, Carys
    oezgueroglu, Mustafa
    Pikiel, Joanna
    Kalofonos, Haralabos P.
    Wojcik, Elzbieta
    Buchler, Tomas
    Swinson, Daniel
    Cicin, Irfan
    Joseph, Mano
    Vynnychenko, Ihor
    Luft, Alexander Valerievich
    Enzinger, Peter C.
    Salek, Tomas
    Papandreou, Christos
    Tournigand, Christophe
    Maiello, Evaristo
    Wei, Ran
    Ferry, David
    Gao, Ling
    Oliveira, Joana M.
    Ajani, Jaffer A.
    CANCERS, 2022, 14 (05)
  • [6] NCI 10066: A phase 1 / 2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma.
    Cecchini, Michael
    LoRusso, Patricia
    Shyr, Yu
    Ivy, S. Percy
    Sklar, Jeffrey
    Dooley, Kirsten
    Lacy, Jill
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer (HER-RAM study).
    Rha, Sun Young
    Kim, Chang Gon
    Jung, Minkyu
    Kim, Hyo Song
    Lee, Choong-kun
    Jeung, Hei-Cheul
    Koo, Dong-Hoe
    Bae, Woo Kyun
    Zang, Dae Young
    Kim, Hyunki
    Chung, Hyun Cheol Cheol
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Nab-paclitaxel plus sintilimab as second-line therapy for advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJA): Preliminary results from an open-label, single-arm, phase 2 study
    Jiang, Zhichao
    Zhang, Wen
    Yang, Lin
    Sun, Yongkun
    Zhao, Yun-Bo
    Deng, Wei
    Zhou, Ai-Ping
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [9] Efficacy and safety of cadonilimab in combination with pulocimab and paclitaxel as second-line therapy in patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer who failed immunochemotherapy: A multicenter, double-blind, randomized trial
    Zhang, Xiaotian
    Wang, Yakun
    Xiang, Xiaojun
    Pan, Hongming
    Zhang, Jingdong
    Chen, Xiaobing
    Ba, Yi
    Ying Jieer
    He, Yifu
    Yin, Xianli
    Xu, Huiting
    Xiao, Li
    Liu, Lian
    Chen, Juan
    Ma, Jiachi
    Shen, Lin
    Liu, Ting
    Liu, Wei
    Li, Baiyong
    Xia, Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Trial in progress: A phase 2, multicenter, open-label study of DKN-01 in combination with tislelizumab and chemotherapy as 1L therapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ; DisTinGuish).
    Lee, Keun-Wook
    Moehler, Markus H.
    Cunningham, David
    Wainberg, Zev A.
    Uronis, Hope Elizabeth
    Oh, Do-Youn
    Kim, In-Ho
    Shim, Byoung Yong
    Sym, Sun Jin
    Altura, Rachel A.
    Stilian, Melissa C.
    Parker, Elizabeth C.
    Klempner, Samuel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS484 - TPS484
12345